Our goal is to empower real-time epidemiological monitoring, outbreak detection and containment, clinical research, and other surveillance tasks requiring rapid response. At ID Genomics, Inc., our mission is to guide antibiotic or other treatment correctly the first time by matching the infecting bug with the correct drug. Our lead product is being developed for urinary tract infection (UTI), a common infection that is at the forefront of the antibiotic resistance crisis. BactNet™ is a reference metadata repository that links bacterial samples, IDG’s proprietary barcodes, and clinical information with responses to commonly prescribed antibiotics. Inexpensive single-locus typing technique which offers a subtyping resolution comparable to MLST and PFGE. ID Genomics, SPC, is offering rapid sequencing of key genomic regions of SARS-CoV-2 able to distinguish thousands of currently circulating variants, with potential detection of novel variants.
Seattle, United States
Founded in 2012
1-10 Employees
Working industry
Biotechnology
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Biotechnology, Genetics, Health Diagnostics, Medical
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
ID Genomics operates in 1 country around the world
Get an overview of the locations of ID Genomics
Location
Country
State
City
Headquarter
United States
Washington
Seattle
Some frequent questions that have been asked about ID Genomics
Where is ID Genomics located?
The company headquarter of ID Genomics is located in Seattle, Washington, United States. It's worth noting, that the company may have more locations
How many employees does ID Genomics approximately have?
As of the latest available information ID Genomics has around 1-10 employees worldwide.
When was ID Genomics founded?
ID Genomics was founded in 2012
In which industries does ID Genomics mainly work?
The company ID Genomics has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to ID Genomics
ID-GENE ecodiagnostics
Geneva, Switzerland
1-10 Employees
2014
ID-GENE provides fast, sensitive and reliable genetic tests for environmental bioassessment and biomonitoring. ID-GENE has developed a deep expertise in molecular ecodiagnostics. ID-GENE offers fast, sensitive and reliable environmental DNA tests to governmental agencies and the industry. ID-GENE uses the high-throughput DNA sequencing technology applied to selected groups of bio-indicators to assess the ecological quality of aquatic ecosystems. ID-GENE uses the high-throughput DNA sequencing technology to identify the community of animals, plants and microbes present in aquatic ecosystems. ID-GENE uses the high-throughput DNA sequencing technology for detection of selected species in environmental DNA samples. We aim to empower environmental agencies, consultancies, and the industry through innovative tools for environmental impact assessment. It offers comprehensive, reliable and cost-effective genetic tests to enable fast and high quality assessment of the biodiversity and environmental monitoring.
PathoGene
Los Angeles, United States
1-10 Employees
2020
Our goal is to provide the necessary tools for doctors and medical staff to make optimal treatment decisions that can ultimately improve public health as a whole. We believe our technology and processes can replace or augment current diagnostic paradigms in a range of settings, such as hospitals, independent diagnostic testing facilities, veterinary and livestock clinics, and research institutions.PathoGene’s patented, fully-automated, sample-to-answer IVD medical device will detect and identify all infectious bacterial, viral, fungal, and parasitic pathogens and profile antimicrobial resistance in clinical samples. Significantly faster and more accurate diagnostic testing improves patient outcomes by reducing hospital length of stay & healthcare costs, lowering risks of long-term complications, and reducing patient mortality. Fully-automated workflows enable untrained laboratory personnel to operate cutting-edge nanopore sequencing technology at a cost comparable to microbiological culture with sensitivity testing. PathoGene's best-in-class diagnostic testing platform will ensure the United States remains prepared for any biosecurity threat, like SARS-COV-2, Monkeypox, filoviruses, anthrax, and other Category A bioterrorism agents.
SmartGene
Bussigny, Switzerland
11-50 Employees
2000
In the late 1990's, SmartGene's founders saw that realizing the promise of routine genetic analysis would require comprehensive, data management solutions to turn sequence data reliably and reproducibly into meaningful results. Consequently, SmartGene was founded to develop, market, and support application-specific solutions for the analysis and management of complex genetic data. SmartGene's North American operations opened in the Research Triangle Park area of North Carolina in 2006. SmartGene’s proprietary technology, the Integrated Database Network System (IDNS) combines Web and database capabilities with advanced bioinformatics and relevant genetic content in application-specific suites. Currently available modules from SmartGene support both Sanger and Next-Generation Sequencing (NGS) and include identification of bacteria and fungi; genotyping and drug resistance assessment for HIV, HCV, and influenza; 16S Microbiome analysis; multilocus sequence typing (MLST) for epidemiology of viruses and bacteria; HLA typing, and certain genetically coded diseases. Customers of SmartGene include diagnostic centers, clinical reference labs, academic medical centers, public health laboratories, S&P 500 companies, research centers, and national networks of sites collaborating securely online. SmartGene's commitment is to provide first-class service to a rapidly growing community of scientists. SmartGene has received certification in accordance with the requirements of the ISO/IEC 27001:2013 Standard.
GeneIQ
Dallas, United States
51-100 Employees
2018
Our goal is to improve the lives of residents by decreasing unscheduled hospital events and mortality rates due to adverse drug reactions and ineffective medications. We are the perfect choice for physician practices, community-based healthcare centers, hospitals, surgery centers, long-term care facilities, and anyone caring for patients. GeneIQ is a molecular diagnostics company that provides actionable insights beyond traditional diagnostics. Through pharmacogenomic and molecular testing for infectious diseases, we deliver personalized clinical guidance to advance patient care. Our non-invasive collection methods may be self-administered, while our test ordering and results portal provides live, user-friendly, 24-hour online access. GeneIQ has been a trusted resource throughout the pandemic and has supported schools, corporations, and community organizations with PCR testing and zero-cost, on-site COVID-19 vaccinations. Through our Vaccine Direct division, an on-site medical team is provided along with a registration platform to ensure efficient processing and that all state reporting requirements are met. GeneIQ is a CLIA licensed and COLA certified laboratory with extensive experience in infectious disease testing.
Day Zero Diagnostics
Boston, United States
11-50 Employees
2016
We are changing the standard of care by delivering the “Holy Grail” of infectious disease diagnostics – rapid, full spectrum organism identification (ID) and antimicrobial resistance and susceptibility (AMR/S) profiling in hours rather than days. Our mission is to empower physicians in the hospital with the information they need to confidently practice precision medicine on patients with a life-threatening infection, rather than “carpet bombing” them with overly broad and toxic therapies that can still be ineffective in a world of multiple drug resistant organisms. Computational biologist with expertise in genomics and machine learning. Expertise in the microbiome and its effect on immune response. Product development leader developing cutting edge solutions in medical technologies and diagnostics. Built and led multi-disciplinary teams from concept to commercialization. The architect of multiple successful regulatory submissions to the FDA and international authorities, including IDE, 510(k), de novo, PMA and CE. Clinical pathology trainee with expertise in microbiology and immunology.
BioGene Ltd
-
11-50 Employees
1993
At BioGene we focus on High Consequence Infectious Diseases (HCIDs). This unique strategy provides actionable results and data in ‘real time’ to assist in triaging, treatment, and surveillance activities to help break onward disease transmission chains and mitigate the effects of High Consequence Infectious Diseases (HCIDs) on society. Everything we do and our continuous research into new innovations is dedicated to supporting At Patient Testing. CENOS is our innovative platform technology which comprises of our portable instrument and Extraction Free (XF) Reagent System. There is no single magic bullet to end pandemics, but there is a combination of measures that will - commitment, finance, global holistic strategy, alerts and preparedness, and leadership. With so many lives at stake, now is the time for resolve.